While there was no change in disability-free survival, the results should impact guidelines, says François Mach.

The CMR GUIDE trial didn’t meet its primary endpoint but did point to possible positives, especially in younger patients.

The US Food and Drug Administration has granted an expanded indication to tirzepatide (Mounjaro) for reducing major adverse ...

Starting evolocumab in the cath lab before PCI did not, however, result in better clinical outcomes in the first year.

Among patients with nonobstructive hypertrophic cardiomyopathy (HCM), the selective cardiac myosin inhibitor aficamten ...

Because of the low number of events in the trial, the findings are thought-provoking but not definitive, one expert says.

At TCT 2025, Jeff Popma interviews Sahar Samimi and Sachin Goel about the simultaneous presentation and publication of their ...

The agency says the company has reported 37 serious injuries and three deaths related to the issue as of August 17.

Compared with standard treatment, an abbreviated regimen was associated with more relapses but didn’t compromise safety.

While there’s no harm in discontinuing for patients who’ve yet to develop ASCVD by age 75, the trial also found no clear ...

Boston Scientific has reported one serious injury, but no deaths, related to the defect. Today the FDA announced a Class I ...

There was a modest gain in the number of days alive and at home after the operation, with a significant savings in blood ...